Ann: COVID19 Vaccine Feasibility Assessment, page-604

I thought here would be good given its for the holders not the sellers, and might have been stated elsewhere so ignore if I'm reposting but I see the following as the reason for the delay - which isn't really a delay, more the process.

https://finance.yahoo.com/news/novavax-eyes-upcoming-phase-3-025911370.html

The Novavax trial is at the final Stage 3

'Phase 3 trials are underway in the UK and enrolment of 15,000 participants was completed in November 2020. Interim data is expected in the first quarter of 2021. More large-scale clinical trials are underway or planned for other countries in late 2020 and early 2021, including South Africa, USA and Mexico. These Phase 3 trials will include 30,000 participants overall.'

This data would support the TGA application that is currently given a 'provisional determination' which seems to my non science mind that its looking good, but needs all the data to be provided once available.

https://www.tga.gov.au/tga-grants-additional-provisional-determination-covid-19-vaccine

So once this comes out globally, I would assume that it gives the green light for both the importation from Europe (supply restraint issue) and the green light for IDT to start the process to manufacture, given CSL have stated they cant do both at once.

disallowed/business/companies/not-infinite-csl-unable-to-quickly-flick-switch-on-vaccine-plans-20210409-p57hsx.html
"Making the Novavax product in Australia would require significant retooling of CSL’s facilities"

and lastly

https://www1.racgp.org.au/newsgp/clinical/astrazeneca-blood-clot-link-increases-importance-o
"AstraZeneca blood clot link increases importance of Novavax"

Thoughts?